Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?

Ítems similars

• Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
  per: Evans, D. Gareth, et al.
  Publicat: (2019)
• Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives
  per: Evans, D Gareth R, et al.
  Publicat: (2013)
• Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
  per: Ahmed, M, et al.
  Publicat: (2010)
• Non-random transmission of mutant alleles to female offspring in BRCA carriers
  per: Evans, D, et al.
  Publicat: (2005)
• Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers
  per: Antoniou, Antonis C, et al.
  Publicat: (2006)